Richtlijn CVRM feb2013 - KNMP

Nawarskas 2011 Nawarskas JJ, Snowden SS. Critical appraisal of ticagrelor in the management of acute
coronary syndrome. Ther Clin Risk manag 2011; 7 : 473-88
NDF 2010
NDF Voedingsrichtlijn voor diabetes type 1 en 2. Nederlandse Diabetes Federatie, Amersfoort,
augustus 2010.
Negi 2010 Negi S, Ballantyne CM. Insights from recent meta-analysis: role of high-density lipoprotein
cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
Lipidol. 2010 Sep-Oct;4(5):365-70.
Clin
Nielsen 2011 Nielsen ML, Pareek M, Henriksen JE. Reduced synthesis of coenzyme Q10 may cause statin
related myopathie- a systematic review. Ugeskr Laeger 2011; 173 (46): 2943-2948.
NISB 2004 Nederlands Instituut voor Sport en Bewegen (NISB)/ Beweegnorm, 3e herziene versie 2004. Te
raadplegen via http://www.nisb.nl/documenten/beweegnorm2004.pdf
Nissen 2004 Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive
compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: a
randomized controlled trail. JAMA 2004; 291: 1071-1080.
Nissen 2005 Nissen SE, Tuczu EM, Schoenhagen P, et al. Statin Therapy, LDL cholesterol, C-reactive
protein, and coronary artery disease. N Eng J Med 2005; 352: 29-38.
Orford 2004
Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, et al. Safety and efficacy of
aspirin, clopidogrel and warfarin after coronary stent placement in patients with an indication for
anticoagulation. Am Heart J 2004; 147: 463-67.
Ortego 1999 Ortego M, Bustos C, Hernandes-Presa MA, Tunon J, Diaz C, Hernandez G, et al. Atorvastatin
reduces NF-KappaB activation and chemokine expression in vascular smooth muscle cells and
mononuclear cells. Atherosclerosis 1999; 147: 253-261.
Osterberg 2005 Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005; 353: 487-497.
Pahor 2000a
Pahor 2000b
Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health
outcomes associated with calcium antagonists compared with other first-line antihypertensive
therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356: 1949-1954.
Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of
ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;
23: 888-892.
Pandor 2009 Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, et al. Ezetimibe monotherapy for
cholesterol lowering in 2722 people: systematic review and meta-analysis of randomized
controlled trials. J Intern Med 2009; 265:568-580.
Parving 2001a
Parving 2001b
Pasceri 2007
Parving HH, Rossing P. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in
patients with type 2 diabetes. Diabetes Care 2001; 24: 177-1780.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan
on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;
345: 870-878.
Pasceri V, Patti G, Speciale G, Prisipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on
use of drug-eluting stents for treatment of acute myocardial infection. Am Heart J 2007; 153: 747-54.
Pasternak 2002 Pasternak RS, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JL, Lenfant C.
ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Stroke 2002; 33: 2337-41.
Patel 2011
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus
warfarin in patients with nonvalvular atrial fibrillation. N Eng J Med 2011; 365 (10): 883-91
Pedersen 2005 Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I et al. High-dose
atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:
IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
The
95
CONCEPT